The inhibition by bacitracin of the en- Bacitracin is an antibiotic produced by strains of Bacillus licheniformis. It is a mixture of closely related compounds, the main component of which (bacitracin A) is a cyclic polypeptide with a peptide side chain ( Fig. 1) (1-3 ). An unusual feature of the structure is the occurrence of a thiazoline ring formed between the L-cysteine and L-isoleucine residues at the N-terminal end of the acylic peptide side-chain. The free amino group of iisoleucine at the N-terminal end is adjacent to the thiazoline ring and is essential for antimicrobial activity. The transformation of bacitracin A to bacitracin F (in which the amino group is replaced by a carbonyl group) results in total loss of antimicrobial activity. A metal ion may be essential for the antimicrobial activity of bacitracin (4-1 1). The antimicrobial activity is stimulated by various metal ions and inhibited by metal-chelating agents, such as EDTA. Spectroscopic evidence for the interaction of bacitracin with metal ions has been obtained. The chelation may involve both the nitrogen of the thiazoline ring and the adjacent free amino-group in isoleucine; this chelation could assist in stabilizing the thiazoline ring, thus hindering the deamination to bacitracin F (10). It has been further postulated that in the zinc-bacitracin A complex, the zinc also coordinates through the imidazole of the histidine residue and the peptide nitrogen of the histidine residue, thus forming a oneto-one complex with bacitracin (10).
Bacitracin is an antibiotic produced by strains of Bacillus licheniformis. It is a mixture of closely related compounds, the main component of which (bacitracin A) is a cyclic polypeptide with a peptide side chain ( Fig. 1) (1-3 ). An unusual feature of the structure is the occurrence of a thiazoline ring formed between the L-cysteine and L-isoleucine residues at the N-terminal end of the acylic peptide side-chain. The free amino group of iisoleucine at the N-terminal end is adjacent to the thiazoline ring and is essential for antimicrobial activity. The transformation of bacitracin A to bacitracin F (in which the amino group is replaced by a carbonyl group) results in total loss of antimicrobial activity.
A metal ion may be essential for the antimicrobial activity of bacitracin (4-1 1). The antimicrobial activity is stimulated by various metal ions and inhibited by metal-chelating agents, such as EDTA. Spectroscopic evidence for the interaction of bacitracin with metal ions has been obtained. The chelation may involve both the nitrogen of the thiazoline ring and the adjacent free amino-group in isoleucine; this chelation could assist in stabilizing the thiazoline ring, thus hindering the deamination to bacitracin F (10) . It has been further postulated that in the zinc-bacitracin A complex, the zinc also coordinates through the imidazole of the histidine residue and the peptide nitrogen of the histidine residue, thus forming a oneto-one complex with bacitracin (10) .
Various biochemical lesions induced by bacitracin have been reported (9) . Several effects, such as inhibition of induced enzyme synthesis and stimulation of efflux of K+ ions, could be ascribed to alterations in cell-membrane function. The antibiotic also inhibits incorporation of ['4C ]aminoacids into cell walls and induces the accumulation of uridine-nucleotide precursors of the wall under conditions in which incorporation of amino acids into protein is unaffected (12) (13) (14) (15) . However, since bacitracin affects protoplasts of bacteria, its action is not limited to effects on cell walls. The precise site of action in cell wall synthesis has been defined as inhibition of the dephosphorylation of C55-isoprenyl pyrophosphate. This reaction is essential for regeneration of the lipid carrier required for the cyclic synthesis of peptidoglycan (16, 17) . In the present paper, data are presented which suggest that bacitracin acts by forming a complex with C55-isoprenyl pyrophosphate (a component of the cell membrane) and divalent cations. The metal ion may serve as a bridge between the antibiotic and the substrate.
MATERIALS AND METHODS
The C55-isoprenyl pyrophosphatase used was that present in membranes of Streptococcus fecalis. The membranes were prepared and washed with EDTA and 2 M LiCl as described previously (through step 2 of the procedure) (Staudenbauer, W. L., and J. L., Strominger, J. Biol. Chem., submitted). The residual LiCl was removed by washing with water and then dialysis against water. Finally, the membranes were lyophilized. This freeze-dried preparation could be stored for at least a year. Before use, it was suspended in water to a protein concentration of 1.1 mg/ml. ). An important observation was that when highly radioactive lipid-P-P was filtered through glass wool or chromatographed on a column of silica gel, the lipid-P-P was irreversibly bound to the glass unless it had previously been silanized with a 5% solution of dimethyldichlorosilane in toluene. Bacitracin was generously given by the Upjohn Co., Kalamazoo, Mich. The general methods and materials used have been described (17, 18 (17) . This dephosphorylation does not require metal ions, as evidenced by the fact that concentrations of EDTA and other metal chelating agents up to 0.05 M have no effect on its activity. However, the addition of EDTA or other chelating agents to a system that had been inhibited to the extent of more than 95% by the addition of bacitracin resulted in restoration of activity to the amount found in the absence of bacitracin (Fig. 2 ). This effect of EDTA is not due to some chemical alteration of the bacitracin molecule produced by EDTA, since after prior incubation of bacitracin with EDTA, the addition of magnesium ions in slight excess of the amount of EDTA added resulted in restoration of the inhibition. The effect was not specific for Mg++, but could also be obtained with Cu++.
Effect of Prior Incubation of Bacitracin with Various Components of the Reaction Mixture in the Presence of Metal Ions.
The sequence of addition of components of the reaction mixture was important in obtaining reproducible results. All of the above experiments had, therefore, been done by addition of the lipid substrate, metal, chelating agent, bacitracin, and enzyme in the sequence indicated. However, if bacitracin, metal ions, and substrate were incubated together before the addition of EDTA, EDTA reversed the inhibition due to bacitracin by only about 30%. On the other hand, prior incubation of enzyme with bacitracin in the presence of a metal ion resulted in normal enzymatic activity when EDTA was added before substrate. These data suggest that a complex is formed between bacitracin, metal ion, and substrate that can be reversed to only a small extent by the addition of EDTA. Similar results were obtained with hydroxyethylenediaminetriacetate and ethylene-bis-(oxyethylenenitrilo)tetraacetate. Experiments were performed essentially as described in the legend to Fig. 2 .
Effects of Various Metals on
The control was obtained by mixing substrate and metal ion to a final concentration of 1 mM, then adding EDTA before bacitracin and enzyme. In the experimental tube, substrate and metal ion were mixed and then bacitracin was added before EDTA and enzyme. The concentration of EDTA was 1.4 mM.
activity on subsequent addition of enzyme was observed ( Table 1) . Treatment of enzyme, substrate, and bacitracin separately with EDTA failed to alter the result of this experiment. § It is presumed that this effect of bacitracin in the absence of added metal is due to the presence of small amounts of metal ions that could not be removed under the conditions used. As bacitracin is known to have a very high affinity for metals (5, 7), it would presumably also scavenge traces of metal ions in the buffers, glassware, etc.
Addition of several divalent cations, Mg++, Ca++, Cu++, and Zn++, further enhanced the inhibition. In each case, the inhibition was relieved if EDTA was added before addition of bacitracin, but not if it was added after bacitracin. Several other metals, Mn++, Fe++, Co++, and Cd++, also enhanced the inhibition by bacitracin, although under our conditions these metals, especially Cd++, also caused some inhibition of the enzyme reaction by themselves. The monovalent cations, Li+, Na+, and K+, failed to enhance the inhibition by bacitracin. More striking, however, is the fact that they relieved the inhibition observed in the absence of added metal ion. This effect was presumably due to displacement from bacitracin of trace amounts of divalent cations by an excess of these monovalent cations.
The Effects of Bacitracin on Enzyme Systems Involving Other Substrates. A model to be presented below suggests that the divalent cation forms a bridge between the pyrophosphate residue in the C55-isoprenyl pyrophosphate and bacitracin. If this is so, then other compounds containing pyrophosphate residues might also be expected to complex with bacitracin. The effects of bacitracin on enzymatic reactions involving inorganic pyrophosphate, ATP, and ADP were therefore examined. Adenylate kinase, ATPase, pyruvate phosphokinase, and inorganic pyrophosphatase were not inhibited by bacitracin at concentrations up to 10 mg/ml. All of these enzymes require Mg++ or another divalent cation for activity and were tested in its presence. In addition, it was already known from the point of inhibition of bacitracin in the cycle of cell wall synthesis that bacitracin does not affect any of the other reactions in the cycle that involve either Cs-isoprenyl phosphate or C55-isoprenyl pyrophosphoryl-sugar compounds, e.g., the initial reaction in which UDP-MurNAc-pentapeptide reacts with C55-isoprenyl phosphate to form lipid-P-P-MurNAc-pentapeptide, or any of the subsequent reactions in which K) I. 2 ), containing 0.35% deoxycholate, 0.02 mM MgC12, and 0.5 mM 2-mercaptoethanol was applied to a column of Sephadex G-25 (1.4 ml in a 1-ml graduated pipet). Fractions of 40,u were collected in a micropipet every 1.5 min: the entire fraction was counted. The first 1 ml of the elution fluid was discarded. The elution of radioactivity was constant after collection of an additional 40 fractions. Bacitracin, 7 acetylglucosamine is added to the lipid intermediate (18) . The effects of bacitracin on C55-isoprenyl phosphate phosphatase (Willoughby, E.. and J. L. Strominger J. Biol. Chem., submitted) and on the ATP-dependent phosphokinase that catalyzes the phosphorylation of free C55-isoprenyl alcohol (19) were also examined; neither enzyme was inhibited by up to 1 mg/ml of bacitracin. On the other hand, marked inhibition of the biosynthesis of squalene and sterols from mevalonic acid, involving short-chain prenyl pyrophosphates as intermediates, has been observed and will be reported subsequently.
Complex Formation between Bacitracin and C55-isoprenyl Pyrophosphate. When a sample of [82P]Cm-isoprenyl pyrophosphate was filtered through a column of Sephadex G-25, in a buffer containing deoxycholate, until it was eluted at a constant rate, the addition of bacitracin resulted in a trough of radioactivity followed by a peak, indicative of the forma-tion of a complex (Fig. 3A) (20) . This result is the opposite of the effect observed in the earlier use of this method, in which a peak was followed by a trough (20) , and must indicate that the complex is included in the gel to a greater extent than is the uncomplexed C55-isoprenyl pyrophosphate. Presumably, the free C55-isoprenyl pyrophosphate is included in a relatively large detergent micelle, which cannot penetrate the gel. In the presence of EDTA, complexation was reduced (Fig. 3B) . No complex formation was observed when C55-isoprenyl phosphate was used (Fig. 3C ).
Molecular Models of Bacitracin and of C-isoprenyl Pyrophosphate. Acid hydrolysis of bacitracin A yields small amounts of two peptides containing the sequence phenylalanyl-isoleucine (1); it is believed that this observation indicates that these two amino acids must lie very close to each other in the structure. A model of bacitracin was built so that the N-terminal amino acid of the acyclic side chain, i-isoleucine, was close enough to interact with the carbonyl carbon of the D-phenylalanine residue in the cyclic portion of the molecule. The thiazoline ring holds the peptide nitrogen of the cysteine residue in the ring and the free amino group of the N-terminal isoleucine residue in a position suitable for the formation of a metal chelate (Fig. 4A) . Moreover, this site lies, facing inwards at the head of a groove into which pyrophosphate can be fit. The metal ion will then coordinate through four points of attachment so that it forms a bridge between the bacitracin and the pyrophosphate. Attachment is made through oxygens of adjacent phosphates in the substrate and through peptide nitrogens of the D-asparagine residue attached to the cyclic ring, and of the a-amino group of i-lysine in the ring at the point where the acyclic peptide side chain is attached to this nitrogen. This coordination is shown in Fig. 4B , with the hydrophobic C55-isoprenoid chain in an extended conformation. The requirement of isoprenyl pyrophosphates for binding, however, indicate that the isoprenoid chain must also interact with the bacitracin. Subsequent studies (manuscript in preparation) have shown that neither inorganic pyrophosphate nor isopentenyl pyrophosphate is complexed in the presence of metal to bacitracin, but C15-farnesyl pyrophosphate forms a strong complex.1 It should be emphasized that no data are available regarding the conformation of bacitracin. Other conformations are possible in which the isoprenyl pyrophosphate can be complexed through the metal ion to bacitracin, including one in which the acyclic peptide side chain is folded on the opposite side of the peptide ring to interact with the phenylalanine residue and another in which the histidine residue (just above the D-asparagine residue as photographed) is brought forward to provide coordination sites for the metal ion. The latter conformation One possible interpretation of the partial reversal of complex formation by EDTA is that EDTA can compete with a portion of the bacitracin-metal-substrate complex in which the hydrophobic chain has not interacted with the bacitracin molecule (Fig. 4B ), but it cannot dissociate the complex in which the isoprenoid chain is fully associated with bacitracin. Another possibility is that the complexes formed with the various components of the bacitracin mixture used in this study differ, and that EDTA can compete for the metal in some of the complexes but not in others.
would account for the known interaction of the histidine residue in bacitracin with the metal ion (10, 11) , but the possibility also needs to be considered that the metal-histidine coordination site would be replaced by metal-pyrophosphate coordination sites in the complex. The present model, presented as a basis for further study, accounts for the failure of bacitracin-metal to complex with the C55-isoprenyl pyrophosphoryl-sugar derivative (since there is no space for the sugar derivatives in the groove into which pyrophosphate fits) or with C55-isoprenyl phosphate (which cannot complex tightly with the metal ion).
Finally, the general effect of bacitracin on various membrane functions (9) could be explained by the distortion of membrane structure that might be expected from the complexation of Cm-isoprenyl pyrophosphate with bacitracin, either due to the removal of the lipid from the membrane or due to the penetration of the membrane by bacitracin. Similarly, the toxicity of bacitracin for animal cells could be due to the complexation of bacitracin with short-chain prenyl pyrophosphates found in animal tissues.
